Olivia has over 20 years of experience in the pharmaceutical industry in a range of project management roles. Olivia was previously Head Of PMO at Eirgen Pharma in Ireland supporting the development of a number of high potency value-added generic R&D developments for global markets, in addition to overseeing the technical transfer of products with a range of development partners. Prior to Eirgen, Olivia was Executive Director of Project Management at Mundipharma where she managed teams in the U.K., Singapore, China and Japan.

Olivia is an experienced project leader and has a broad range of experience leading R&D developments from Phases I through to commercialisation and market access in a range of therapeutic indications including pain, respiratory, immunological disorders, addiction and BPH, for markets across the EU, US, Asia Pacific and LATAM regions. During her time at Mundipharma she successfully led a number of co-developments with partner companies and academia and is highly experienced in leading virtual teams to success.

Previous to her time in project management, Olivia worked in regulatory affairs with roles in industry and at the MHRA in London.

Dr. Jasmin Kee is a process and manufacturing operations specialist with over 15 years’ experience in the Cell and Gene Therapy industry. She has worked for companies including Intercytex, Organogenesis, Reneuron and Cell Medica and now provides consultancy in areas including manufacturing process design, operational strategic planning and design of cGMP facilities. Jasmin started her career as a Process Engineer and moved into roles of increasing responsibility including Head of Engineering and VP of Manufacturing Operations (EU). Her experience includes development and manufacturing of tissue engineered, stem cell and CAR-T products as well as blood plasma products and consumer goods. She has built teams responsible for translation of development process to GMP, scale-up, automation and technology transfer for clinical trial and commercial products. She has led the design of cGMP manufacturing facilities in the US and UK and developed organisational strategies to support business growth.

During the COVID-19 Pandemic, Jasmin was and industry advisor to the UK Government Vaccines Taskforce and served as Technical Director and Deputy Programme Director overseeing the supply of COVID-19 vaccine to the UK. She is also passionate about building links between academia and industry and is an industry advisory board member for University College London, Biochemical Engineering Department

Paul is a recognised pioneer in the field of Regenerative Medicine and has over 25 years’ experience in the US and UK in the commercialisation of various Regenerative Medicine and Cell Therapy products in both public and private Companies. Over the years, he has built a successful track record in all aspects of the business, from carrying out translational research, in-licensing technologies from Universities and out-licensing products to a variety of HealthCare Companies, designing, obtaining regulatory approval and running clinical trials in the US, Canada, UK and Europe, designing, building and operating GMP facilities, founding biotech companies, and launching, marketing and selling cell based products in the US and UK.

When at Organogenesis Inc, he was the lead inventor on patents for the first multi-cell therapy approved by the FDA and was involved in all stages of the development of this product from the bench, through the clinical trial process, development of a licensing and marketing partnership and the eventual approval and launch in the US.  This product has now treated well over half a million patients and is the largest selling manufactured cell therapy in the world. After Organogenesis, Paul returned to the UK and was the sole founder of Intercytex. He served as CEO for the first 5 years and under his leadership the company grew rapidly, attracted significant VC investment from Europe, the US and Asia. During this period, Intercytex developed several products that reached the clinic, including the world’s first cell therapy clinical trial to induce new hair formation and carried out with Bessam and Nilofer Farjo.

Paul has numerous patents and publications in the field and is often invited to speak at International Conferences and sit on a variety of panels, grant funding bodies and regulatory committees. He is co-editor of the Journal of Regenerative Medicine, a co-Director of the Doctoral Training Centre in Regenerative Medicine at Manchester University and Industrial Director of Regener8.

Mr Paul Francis Gregory Binney is CFO at CellResearch Corp Group of Companies. With extensive experience in distribution, Paul also heads the distribution division at CellResearchCorp. Paul is currently also Chief Financial Officer and Company Secretary of Lafe Corporation Limited, a Singapore Listed Investment Holding Company.

Paul has extensive experience in sales and marketing, finance and corporate accounting in manufacturing, distribution and operations worldwide. He has significant experience gained in operational reviews worldwide for investment businesses and banking, especially in reviewing acquisition and disposal projects, which has led to a wealth of knowledge and contacts for capital funding. The combination of managing operations as Group Finance Director covering physical product, hedging and financial instruments has led to his developing significant skills in operational based assessments and in Sarbanes-Oxley compliance, US GAAP and IFRS application.

Paul holds an MBA from the University of Warwick and a Bachelor of Commerce (Honours) Degree from the University of Birmingham. He is a member of the Institute of Chartered Accountants in England and Wales.

Dr Schiweck is the Intellectual Property Counsel at CellResearch Corporation Group of Companies. Dr Schiweck has worked with CellResearch’s IP portfolios since 2004 and has been key to building up CellResearch’s core IPR.

Dr Wolfram Schiweck has been practicing IP law since 1997 and is a founding partner of Schiweck Weinzierl Koch, a European patent attorney firm specializing in chemistry, biotechnology and life sciences. Before starting Schiweck Weinzierl Koch, he was the head of the chemistry and life science practice group of Viering, Jentschura & Partner and resident partner of the Singapore office. A main focus of work is the drafting and word-wide prosecution of patent applications in the chemical and pharmaceutical field including opposition and invalidation proceedings and the examination of intellectual property rights’ portfolios of companies (due diligence).

Due to his long stay in Asia, Wolfram is also very familiar with patent prosecution in the Asia-Pacific region. Wolfram is a registered European patent attorney, German patent attorney and Singapore patent agent. He holds a Master Degree in Chemistry and received a Ph.D. in Biochemistry for his work on antibody design at the Max-Planck-Institute of Biophysics in Frankfurt, Germany.

Gavin Tan is a founding director and CEO of the CellResearch Corporation Group of Companies. Gavin is a serial entrepreneur having founded a series of Biotech Start-Ups as well as one of Singapore’s most successful multi-family offices. In the early 2000s as Singapore shifted its focus away from manufacturing and towards creating a vibrant life sciences ecosystem Gavin co-founded CellResearch Corporation. Under his leadership, CellResearch has become one of Singapore’s most promising Biotech platforms. He has been instrumental in charting the strategy and growth of CellResearch Corporation and its subsidiaries, making the early decision to leverage CellResearch’s platform technology across multiple business sectors. Gavin has now stewarded the creation of a strong crop of subsidiary businesses covering drug development, Cosmeceuticals and Cord banking.
Prior to co-founding his biotechnology and family office businesses, Gavin worked for over 22 years in Asian financial markets. For seven years prior to assuming his current role at CellResearch Corporation, he was Head of Institutional Sales at Nomura Securities Singapore Pte Ltd where he was responsible for directing and developing the firm’s institutional equity business in Singapore and Malaysia. He has extensive experience in developing and marketing equities products as well as growing an international business.

Gavin holds executive directorships and non-executive directorships in several companies including Aglaia Family Office Pte Ltd, an Asian-based diversified asset management company and multi-family office.

Mr Lim is a Founding Director of CellResearch Corporation Group of Companies which is focused on the research and commercialisation of Umbilical Cord Lining membrane Stem Cells, a patented technology that he co-developed with Professor Phan.

He received his undergraduate professional training at Cambridge University, and postgraduate training in London.

In addition to directing the Skin Cell Research Group at the National University of Singapore where he has an academic affiliation, he has international collaborations for research, reviews grants both locally and internationally, and is a peer reviewer for local and international scientific and professional journals.</span

Professor Phan is a founding director and CSO of CellResearch Corporation Group of Companies. A graduate of the Military Medical University, Hanoi, Vietnam in 1991, Prof. Phan Toan Thang has had a strong interest in wound healing since the earliest days of his medical and scientific career. His interest led him to hands-on experience during his four-year surgical residency in Hanoi at the National Institute of Burns and at the Army Hospital 103. Prof. Phan’s commitment and excellence in laboratory research was proven when he spent two years at the prestigious Wound Healing Institute and Department of Dermatology in Oxford, England.

He arrived in Singapore in 1997 to join the Department of Plastic Surgery at the Singapore General Hospital. In 1998, he met Mr Ivor Lim, and together they established the Skin Cell Research Group (currently Wound Healing and Stem Cell Research Group) focusing on skin and keloid scar biology. The Wound Healing and Stem Cell Research Group was the first group in the world to explore the role of epithelial-mesenchymal interactions in keloid pathogenesis, and is recognised today as one of the world leading groups in keloid and scar biology research.

Prior to taking up his faculty position at the Department of Surgery, Yong Loo Lin School of Medicine and Faculty of Dentistry at the National University of Singapore, Prof. Phan completed two years of post-doctoral research at the Stanford University Children Surgical Research Laboratory.

Prof. Phan is author of more than 80 publications in international peer-reviewed journals, two book chapters, has more than 35 granted patents and serves as a reviewer for prestigious international scientific journals as well as local and international research funding bodies. His recent innovative research work is the discovery of a novel source of stem cells from the umbilical cord lining membrane with translational potential for regenerative medicine, tissue engineering and cell-based therapy.

Andrew Boulton is Professor of Medicine with a special interest in diabetes and its complications at the University of Manchester and Consultant Physician at Manchester Royal Infirmary. His clinical role includes inpatient supervision of patients with diabetic complications and outpatient clinics at the Manchester Diabetes Centre. As director of the DIALEX (Diabetes Lower Extremity) Research Group Prof Boulton is responsible for the planning of clinical research into diabetic complications, developing collaborative research with colleagues in Europe and North America, running undergraduate and postgraduate teaching in diabetes and its complications.

Prof Boulton currently holds the appointment of Professor of Medicine (Diabetes) at the University of Manchester and is a Consultant Physician at the Manchester Royal Infirmary. He has published over 300 peer review papers and currently holds major grants. Prof Boulton was the first Awardee of the International Award into Diabetic Foot Research (1995) and has also received the Castelli-Pedroli Prize from the European Association for the Study of Diabetes (2003), the Roger Pecoraro Award from the American Diabetes Association (1996) and the Edward Olmos Award for Advocacy in the Prevention of Amputation in Diabetes (2005).

Prof Boulton is currently an Associate Editor for Diabetes Care as well as being on the Editorial Board of Current Diabetes reports and the International Diabetes Monitor. He was formally Editor of Diabetic Medicine (1991-1995). His other current appointments include being the advisor to the NIH for the EDIC Study (Epidemiology of Diabetes and its Complications), the follow up of the DCTT Study From 2002 to 2004 Andrew Boulton was Professor of Medicine at the University of Miami and he still holds a visiting professorship to the Diabetes Research Institute of that University

Dr. Armstrong is Professor of Surgery with Tenure at the University of Southern California. Dr.Armstrong holds a Master of Science in Tissue Repair and Wound Healing from the University of Wales College of Medicine and a PhD from the University of Manchester College of Medicine, where he was appointed Visiting Professor of Medicine. He is founder and co-Director of the Southwestern Academic
Limb Salvage Alliance (“SALSA”).

Dr. Armstrong has produced more than 600 peer-reviewed research papers in dozens of scholarly medical journals as well as over 100 books or book chapters. He is founding co-Editor of the American Diabetes Association’s Clinical Care of the Diabetic Foot, now entering its fourth edition

Armstrong is Director of USC’s National Science Foundation (NSF) funded Center to Stream Healthcare in Place (“C2SHiP.org”) which places him at the nexus of the merger of consumer electronics, wearables and medical devices in an effort to maximize hospital-free and activity-rich days.

Dr. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards and degrees by universities and international medical organizations including the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected into the Podiatric Medicine Hal l of Fame. He was the first surgeon to be appointed University Distinguished Outreach Professor at the University of Arizona. He was the first podiatric surgeon to become a member of the Society of Vascular Surgery and the first US podiatric surgeon named fellow of the Royal College of Surgeons, Glasgow. He is the 2010 and youngest ever recipient of the ADA’s Roger Pecoraro Award, the highest award given in the field.

Dr. Armstrong is past Chair of Scientific Sessions for the ADA’s Foot Care Council, and a past member of the National Board of Directors of the American Diabetes Association. He sits on the Infectious Disease Society of America’s (“IDSA”) Diabetic Foot Infection Advisory Committee and is the US appointed delegate to the International Working Group on the Diabetic Foot. Dr. Armstrong is the founder and co-chair of the International Diabetic Foot Conference (“DF-Con”), the largest annualinternational symposium on the diabetic foot in the world. He is also the Founding President of the American Limb Preservation Society (ALPS), a medical and surgical society dedicated to building interdisciplinary teams to eliminate preventable amputation in the USA and worldwide.